Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Talley

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|February 23, 1995
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery diseaseC B Treasure, J L Klein, W S Weintraub, et al.
Circulation|October 1, 1994
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplastyJ E Tcheng, S G Ellis, B S George, et al.
Circulation|October 1, 1990
Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery. In-hospital and late clinical outcome at 5 yearsJ D Talley, W S Weintraub, G S Roubin, et al.
American Heart Journal|May 29, 2001
Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial RegistryJ G Webb, T A Sanborn, L A Sleeper, et al.
The American Journal of Cardiology|March 1, 1997
Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.
The New England Journal of Medicine|August 26, 1999
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic ShockJ S Hochman, L A Sleeper, J G Webb, et al.
The American Journal of Cardiology|November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.
The American Journal of Cardiology|March 18, 1999
Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplastyJ C Blankenship, M W Krucoff, S W Werns, et al.
Circulation|August 15, 1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|February 23, 1995
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery diseaseC B Treasure, J L Klein, W S Weintraub, et al.
Circulation|October 1, 1994
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplastyJ E Tcheng, S G Ellis, B S George, et al.
Circulation|October 1, 1990
Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery. In-hospital and late clinical outcome at 5 yearsJ D Talley, W S Weintraub, G S Roubin, et al.
American Heart Journal|May 29, 2001
Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial RegistryJ G Webb, T A Sanborn, L A Sleeper, et al.
The American Journal of Cardiology|March 1, 1997
Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon PumpJ D Talley, E M Ohman, D B Mark, et al.
The New England Journal of Medicine|August 26, 1999
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic ShockJ S Hochman, L A Sleeper, J G Webb, et al.
The American Journal of Cardiology|November 13, 2001
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study)J E Tcheng, J D Talley, J C O'Shea, et al.
The American Journal of Cardiology|March 18, 1999
Comparison of slow oscillating versus fast balloon inflation strategies for coronary angioplastyJ C Blankenship, M W Krucoff, S W Werns, et al.
Circulation|August 15, 1996
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC InvestigatorsD B Mark, J D Talley, E J Topol, et al.
Circulation|February 18, 1997
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI InvestigatorsE M Ohman, N S Kleiman, G Gacioch, et al.
Pageof 16